This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Cigna Q3 Earnings Beat Estimates on Evernorth Health Unit Strength
by Zacks Equity Research
CI's Q3 earnings and revenues beat estimates as Evernorth Health Services powers growth despite healthcare headwinds.
Cigna (CI) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Cigna (CI) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cigna (CI) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Cigna (CI) delivered earnings and revenue surprises of +1.69% and +3.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Does UnitedHealth Stock Have More Upside After Q3 Earnings?
by Shaun Pruitt
UnitedHealth Group's (UNH) stock hasn't received the post-earnings rally that investors may have hoped for, but the medical giant was able to provide subtle signs that its operations are stabilizing.
Will Lower Premiums Affect Cigna's Q3 Earnings? Key Insights Here
by Zacks Equity Research
CI's Q3 results hinge on strong Evernorth growth and surging investment income, but lower premiums and rising costs may weigh on margins.
Centene Q3 Earnings Beat Estimates on Increasing Premium
by Zacks Equity Research
CNC's Q3 earnings beat estimates as strong premium growth and rising membership in PDP and Marketplace units offset higher medical costs.
UnitedHealth Q3 Earnings Beat on Rising Commercial Membership
by Zacks Equity Research
UNH's Q3 earnings beat estimates on solid commercial membership gains and Optum Rx strength, though profits fall sharply on rising medical costs.
Ahead of Cigna (CI) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top-and-bottom-line estimates for Cigna (CI), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2025.
Molina (MOH) Q3 Earnings Lag Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of -53.65% and +5.28%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
HQY Expands Access With GLP-1 Telehealth & Direct HSA Platforms
by Zacks Equity Research
HealthEquity rolls out GLP-1 telehealth and direct HSA enrollment platforms, targeting affordability and growth amid rising healthcare costs and regulatory expansion.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Humana (HUM) Moves 4.0% Higher: Will This Strength Last?
by Zacks Equity Research
Humana (HUM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Will Cigna (CI) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Cigna (CI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Humana Benefits From Rising Premiums Amid High Benefit Ratio
by Zacks Equity Research
HUM gains from rising premiums, Medicare growth and CenterWell expansion, but faces pressure from high benefit ratios and costs.
Cigna to Support Cleerly's AI Cardiovascular Imaging Solutions
by Zacks Equity Research
CI expands coverage to Cleerly's AI cardiovascular imaging, boosting access, early detection and digital healthcare adoption.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
CVS Health Steps Up to Bolster Oak Street as Cost Pressures Mount
by Moumi Mondal
CVS trims its outlook as Oak Street faces rising medical costs, but new leadership and tech upgrades aim for steady growth.
Zacks Industry Outlook Highlights Cigna and Humana
by Zacks Equity Research
Cigna and Humana stand out in the HMO space, leveraging growth platforms and Medicare demand despite cost and regulatory pressures.
2 HMO Stocks Poised to Thrive Despite Escalating Medical Costs
by Debasmita Chatterjee
The Medical-HMO industry benefits from strength in commercial plans, M&A and expected Medicare rate hikes, but rising costs, regulatory shifts and workforce shortages strain margins. CI and HUM are likely to navigate industry storms.
Will UnitedHealth's Push for Access to Trump Calm Investor Jitters?
by Kaibalya Pravo Dey
UNH doubles lobbying spend, reshapes legal team and seeks Trump access amid regulatory risks.
CVS Health Trades Cheaper Than Industry: How to Play the Stock?
by Moumi Mondal
CVS' diversified model, digital push and Aetna stabilization highlight a compelling investment story.
CVS Health Services' Q2 AOI Falls Despite Sales Gain: More Risk Ahead?
by Moumi Mondal
CVS Health's Q2 Health Services revenues climb 10%. Yet, AOI slips as cost pressures and Oak Street's rising MBR ail.
Food as Medicine: Elevance Health & NACHC Integrate Nutrition in Care
by Zacks Equity Research
ELV partners with NACHC to bring Food as Medicine into primary care, targeting nutritional insecurities and chronic disease.
Centene Loses 57% YTD, Incurs Loss in Q2: How to Play the Stock
by Tanuka De
CNC plunges 57% YTD after its first quarterly loss in over a decade, with analysts slashing 2025 earnings outlook by 70%.
Why Cigna (CI) is a Great Dividend Stock Right Now
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Cigna (CI) have what it takes? Let's find out.